Acurx Pharmaceuticals

As of March 31, 2026, cash was about 9.3 million dollars with approximately 2.5 million dollars in current liabilities; the auditor expressed substantial doubt about going concern in the 2025 10‑K. The company is funding operations via an equity line of credit and an April 2026 registered direct offering with warrants, implying dilution risk.

There is no debt, but runway for Phase 3 requires additional, likely dilutive, capital or a partnership.